Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda and Eisai submit application for proton pump concomitant therapy

Takeda and Eisai submit application for proton pump concomitant therapy

1st October 2009

Takeda, in partnership with Eisai, has announced that it has submitted an application for the use of proton pump inhibitors with concomitant therapy for the treatment of helicobacter pylori.

Overall, three proton pump inhibitors – lansoprazole, omeprazole and rabeprazole sodium – are involved in the application and are marketed under four brand names.

The concomitant treatment constitutes a proton pump inhibitor, amoxicillin hydrate and either clarithromycin or metronidazole and is indicated for the eradication of H pylori in gastric mucosa-associated lymphoid tissue lymphoma in the stomach after endoscopic resection of early stage gastric cancer and idiopathic thrombocytopenic purpura.

According to the firms involved, approval of the treatment will result in the significant improvement of quality of life for sufferers of these conditions.

In other recent Takeda news, the firm announced through its wholly-owned subsidiary Millennium: The Takeda Oncology Company in September that a clinical trial into its drug TAK-700 was ready to be taken to the next stage.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.